中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

133 records (took 0.037 seconds)

    ANTI MIF ANTIBODIES
    93.
    发明申请
    ANTI MIF ANTIBODIES 审中-公开
    抗MIF抗体

    公开(公告)号：US20150023978A1

    公开(公告)日：2015-01-22

    申请号：US14157967

    申请日：2014-01-17

    Applicant: Baxter International Inc. ,  Dyax Corp. ,  Baxter Healthcare SA

    Inventor： Randolf Kerschbaumer ,  Friedrich Scheiflinger ,  Manfred Rieger ,  Michael Thiele ,  Geert C. Mudde ,  Juergen Muellberg ,  Rene Hoet

    IPC: C07K16/24

    CPC classification number: C07K16/24 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.

    Abstract translation: 本发明涉及特异性结合巨噬细胞迁移抑制因子（MIF）的C端或中心区域的单克隆抗体及其抗原结合部分。 这些抗MIF抗体及其抗原结合部分进一步抑制人MIF生物学功能。 本发明还涉及衍生自抗MIF抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及鉴定抗MIF抗体的方法，包含这些抗体的药物组合物和使用这些抗体和组合物用于治疗MIF相关病症的方法。

    NOVEL FAB FRAGMENT LIBRARIES AND METHODS FOR THEIR USE
    94.
    发明申请
    NOVEL FAB FRAGMENT LIBRARIES AND METHODS FOR THEIR USE 有权
    新的FAB片段图书馆及其使用方法

    公开(公告)号：US20140200165A1

    公开(公告)日：2014-07-17

    申请号：US14090842

    申请日：2013-11-26

    Applicant: Dyax Corp.

    Inventor： Hendricus Renerus Jacobus Mattheus Hoogenboom

    IPC: C07K16/26

    CPC classification number: C07K16/26 ,  C07K16/00 ,  C07K16/18 ,  C07K2317/55 ,  C40B50/06

    Abstract: The present invention provides Fab libraries and methods for using the Fab libraries to obtain antibodies against a target. The Fab library of the invention contains at least 109 different Fabs, and in some embodiments, at least 1010 different Fabs. The Fab libraries of the invention are used to isolate polyclonal or monoclonal Fabs that bind with high specificity to targets.

    Abstract translation: 本发明提供Fab文库和使用Fab文库获得针对靶抗体的方法。 本发明的Fab文库含有至少109个不同的Fab，并且在一些实施方案中包含至少1010个不同的Fab。 本发明的Fab文库用于分离以高特异性结合靶标的多克隆或单克隆Fab。

    Methods for preserving organs and tissues
    96.
    发明申请
    Methods for preserving organs and tissues 有权
    保存器官和组织的方法

    公开(公告)号：US20040053206A1

    公开(公告)日：2004-03-18

    申请号：US10456981

    申请日：2003-06-06

    Applicant: Dyax Corp.

    Inventor： Marco Cicardi ,  Luigi Bergamaschini

    IPC: A01N001/02

    CPC classification number: A01N1/02 ,  A01N1/0226

    Abstract: The invention relates to a method for preserving an organ or tissue comprising contacting the organ or tissue with an effective amount of a kallikrein inhibitor and solutions useful for such a method. Also provided is a method for reducing reperfusion injury of an organ during surgery and/or following removal of the organ from a subject comprising placing the organ in an organ storage and preservative solution, wherein the solution comprises a kallikrein inhibitor.

    Abstract translation: 本发明涉及一种用于保存器官或组织的方法，包括使器官或组织与有效量的激肽释放酶抑制剂和用于该方法的溶液接触。 还提供了一种减少手术期间和/或从受试者去除器官后器官的再灌注损伤的方法，包括将器官置于器官储存和防腐溶液中，其中该溶液包含激肽释放酶抑制剂。

    Modular recombinatorial display libraries
    97.
    发明申请
    Modular recombinatorial display libraries 审中-公开
    模块化重组显示库

    公开(公告)号：US20030186223A1

    公开(公告)日：2003-10-02

    申请号：US10378557

    申请日：2003-03-03

    Applicant: Dyax Corp.

    Inventor： Robert C. Ladner

    IPC: C12Q001/70 ,  C12Q001/68

    CPC classification number: C40B40/02 ,  C12N15/1037

    Abstract: Modular display libraries are disclosed characterized by a display having two or more variable regions connected with constant regions encoded by DNA segments that include a restriction endonuclease cleavage site. The segments encoding modular variable regions can be recombined in anther position in the display vector or rearranged to extend the diversity of the original modular library.

    Abstract translation: 公开的模块化显示库的特征在于具有两个或更多个可变区的显示器，所述可变区与包含限制性内切核酸酶切割位点的DNA片段编码的恒定区连接。 编码模块化可变区域的区段可以在显示向量中的另一位置重新组合或重新排列，以扩展原始模块库的多样性。

    ANTIBODIES BINDING TO PHOSPHORYLCHOLINE (PC) AND/OR PC CONJUGATES
    99.
    发明申请
    ANTIBODIES BINDING TO PHOSPHORYLCHOLINE (PC) AND/OR PC CONJUGATES 有权

    公开(公告)号：US20210230310A1

    公开(公告)日：2021-07-29

    申请号：US17229806

    申请日：2021-04-13

    Applicant: Athera Biotechnologies AB ,  Dyax Corp.

    Inventor： Knut PETTERSSON ,  Ola CAMBER ,  Dan SEXTON ,  Andrew E. NIXON

    IPC: C07K16/44 ,  C07K16/18

    Abstract: The present invention relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein— (a) the VH domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence comprising an amino acid sequence having at least 20%, 40%, 60%, 80% or 100% sequence identity to the sequence of SEQ ID NO: 7; a CDR2 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 41%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 88%, 94%, or 100% sequence identity to the sequence of SEQ ID NO: 8; and a CDR3 sequence comprising an amino acid sequence having at least 11%, 22%, 33%, 44%, 55%, 66%, 77%, 88% or 100% sequence identity to the sequence of SEQ ID NO: 9 or 10; and/or (b) the VL domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR4 sequence comprising an amino acid sequence having at least 7.5%, 15%, 23%, 30%, 38%, 46%, 53%, 61%, 69%, 76%, 84%, 92% or 100% sequence identity to the sequence of SEQ ID NO: 11; a CDR5 sequence comprising an amino acid sequence having at least 14%, 28%, 42%, 57%, 71%, 85% or 100% sequence identity to the sequence of SEQ ID NO: 12; a CDR6 sequence comprising an amino acid sequence having at least 9%, 18%, 27%, 36%, 45%, 54%, 63%, 72%, 81%, 90% or 100% sequence identity to the sequence of SEQ ID NO: 13.

Patent Agency Ranking